EGFR and non-small cell lung carcinoma: Further investigations with larger prospective cohorts are warranted to validate and expand upon our findings, as well as to unravel the complex interplay between EGFR mutations, immune signaling, and PD-L1 expression in EGFR-mutated NSCLC.